Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Oncology

Long-term Monitoring and Managing Malignancy Risk

At a Glance

Patients with Ollier disease face a 5% to 50% lifetime risk of their benign bone tumors becoming malignant. The 2023 AACR guidelines recommend a baseline whole-body MRI followed by lifelong routine monitoring to catch changes early. Patients should watch for red-flag symptoms like pain at rest.

While the majority of enchondromas in Ollier disease are benign, the most significant long-term challenge is the lifetime risk of these lesions transforming into a malignancy (cancer) [1][2]. Current research indicates that the lifetime risk of developing a malignancy—most commonly chondrosarcoma—is estimated to be between 5% and 50% [2][3]. Individual risk varies significantly based on the extent and location of the lesions [2][3]. Because of this, lifelong, proactive monitoring is the standard of care to ensure that any changes are caught early when they are most treatable [1][4].

The 2023 Surveillance Guidelines

In 2023, the American Association for Cancer Research (AACR) Childhood Cancer Predisposition Workshop established new consensus guidelines for monitoring patients with Ollier disease and Maffucci syndrome [1]. These guidelines move toward a more comprehensive approach to ensure nothing is missed:

  • Baseline Whole-Body MRI (WBMRI): Every newly diagnosed patient should receive a baseline whole-body MRI [1]. This “master map” identifies the location and size of all existing enchondromas, providing a critical point of comparison for all future scans [1][4].
  • Routine Monitoring: After the baseline, patients undergo routine clinical exams and imaging [1]. The exact frequency of follow-up imaging will be tailored by your specialist based on your specific case, but the goal is consistent, lifelong surveillance [1][4].
  • Symptom Awareness: Families are educated to watch for “red flags,” such as a known bump that suddenly grows rapidly, persistent pain that occurs at rest, or pain that wakes a person from sleep [3][1].

What Radiologists Look For

When reviewing your MRI, specialized radiologists look for specific “activity” within a lesion that might suggest it is changing from benign to malignant. These features include:

  • Bone Marrow Edema: Swelling or fluid buildup inside the bone surrounding a lesion [5].
  • Periosteal Reaction: Evidence that the bone’s outer “skin” is being irritated or pushed by the growth [5].
  • Soft Tissue Expansion: The growth of the tumor beyond the bone and into the surrounding muscles or tissues [5].

Beyond the Bones

Because Ollier disease is caused by a “mosaic” genetic mutation in the IDH1 or IDH2 genes, other parts of the body can occasionally be affected [6][7]. While skeletal risks are the primary focus, your medical team should also be aware of the rare potential for extra-skeletal conditions. While these occurrences are exceedingly rare and should not be an immediate cause for panic, they include:

  • Gliomas: Brain tumors that can share the same genetic mutation as the bone lesions [8][9].
  • Ovarian Tumors: Specifically juvenile granulosa cell tumors (JGCT), which may present as an abdominal mass or unusual hormonal changes in young female patients [10][11].

Addressing ‘Scanxiety’

It is completely normal to experience scanxiety—the intense anxiety and distress that occurs before, during, and after a scheduled scan [12][13]. Research shows this distress is often highest during the “scan-to-results” waiting period [12][14].

To help manage this burden, experts suggest:

  1. Clear Communication: Establish a plan with your doctor for exactly how and when you will receive results [15][13].
  2. Normalization: Viewing these scans as a “routine check-up” rather than an emergency can help reduce anticipatory anxiety over time [16][17].
  3. Active Coping: Using distraction techniques and focusing on the present moment during the waiting period can significantly lower stress levels [18][19].

Common questions in this guide

What is the risk of cancer with Ollier disease?
The lifetime risk of an enchondroma transforming into cancer, most commonly chondrosarcoma, is estimated to be between 5% and 50%. Your individual risk varies significantly based on the size, extent, and location of your specific bone lesions.
How often do I need an MRI for Ollier disease?
The 2023 AACR guidelines state that every newly diagnosed patient should receive a baseline whole-body MRI to map out all lesions. After this baseline, your specialist will tailor the frequency of your follow-up imaging based on your specific case for lifelong surveillance.
What symptoms should I watch for between scans?
You should contact your doctor if a known bump suddenly grows rapidly, if you have persistent pain while resting, or if pain wakes you or your child up from sleep. These are considered red-flag symptoms that may require an immediate, unscheduled scan.
What does a radiologist look for on my MRI?
Radiologists look for signs of activity that suggest a tumor is becoming malignant. These include bone marrow edema (swelling inside the bone), a periosteal reaction (irritation on the bone's outer skin), or a tumor growing beyond the bone and into surrounding soft tissues.
Can Ollier disease cause tumors outside of the bones?
Yes, although it is exceedingly rare. Because Ollier disease is driven by a genetic mutation, it can occasionally affect other parts of the body. Your medical team will monitor for rare extra-skeletal risks, such as certain brain tumors (gliomas) and specific ovarian tumors.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the official protocol at this center for our first baseline whole-body MRI, and how frequently will it be repeated?
  2. 2.If a lesion shows bone marrow edema or a periosteal reaction on MRI, what are the next diagnostic steps (e.g., biopsy or more frequent imaging)?
  3. 3.How will our medical team monitor for non-skeletal risks, such as gliomas or ovarian tumors, in addition to the bone lesions?
  4. 4.Can we establish a 'results plan'—who will call us with scan findings, and what is the typical turnaround time?
  5. 5.Are there specific red-flag symptoms, like night pain or rapid growth, that should trigger an immediate unscheduled scan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Update on Cancer Screening in Children with Syndromes of Bone Lesions, Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome, and Other Rare Syndromes.

    Michaeli O, Kim SY, Mitchell SG, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2025; (31(3)):457-465 doi:10.1158/1078-0432.CCR-24-2171.

    PMID: 39601780
  2. 2

    Natural history of Ollier disease and Maffucci syndrome: Patient survey and review of clinical literature.

    El Abiad JM, Robbins SM, Cohen B, et al.

    American journal of medical genetics. Part A 2020; (182(5)):1093-1103 doi:10.1002/ajmg.a.61530.

    PMID: 32144835
  3. 3

    Ollier Disease: A Case Series and Literature Review.

    Markevičiūtė V, Markevičiūtė MŠ, Stravinskas M

    Acta medica Lituanic 2021; (28(1)):181-188 doi:10.15388/Amed.2021.28.1.8.

    PMID: 34393643
  4. 4

    Maffucci Syndrome with Clival Enchondroma in Nasopharynx: A Case Report.

    Velagapudi S, Alshammari SM, Velagapudi S

    Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India 2019; (71(Suppl 1)):652-656 doi:10.1007/s12070-018-1463-8.

    PMID: 31742037
  5. 5

    MRI features of low-grade and high-grade chondrosarcoma in enchondromatosis.

    Sharif B, Rajakulasingam R, Sharifi S, et al.

    Skeletal radiology 2021; (50(8)):1637-1646 doi:10.1007/s00256-021-03718-7.

    PMID: 33484272
  6. 6

    Update on the imaging features of the enchondromatosis syndromes.

    Sharif B, Lindsay D, Saifuddin A

    Skeletal radiology 2022; (51(4)):747-762 doi:10.1007/s00256-021-03870-0.

    PMID: 34302201
  7. 7

    Gene of the month: IDH1.

    Bruce-Brand C, Govender D

    Journal of clinical pathology 2020; (73(10)):611-615 doi:10.1136/jclinpath-2020-206813.

    PMID: 32727816
  8. 8

    Characteristics of gliomas in patients with somatic IDH mosaicism.

    Bonnet C, Thomas L, Psimaras D, et al.

    Acta neuropathologica communications 2016; (4()):31 doi:10.1186/s40478-016-0302-y.

    PMID: 27036230
  9. 9

    Brain Gliomas and Ollier Disease: Molecular Findings as Predictive Risk Factors?

    Corvino S, Mariniello G, Corazzelli G, et al.

    Cancers 2022; (14(14)) doi:10.3390/cancers14143464.

    PMID: 35884525
  10. 10

    The association of enchondromatosis with malignant transformed chondrosarcoma and ovarian juvenile granulosa cell tumor (Ollier disease).

    Burgetova A, Matejovsky Z, Zikan M, et al.

    Taiwanese journal of obstetrics & gynecology 2017; (56(2)):253-257 doi:10.1016/j.tjog.2017.02.002.

    PMID: 28420520
  11. 11

    Genetic Causes of Rare Pediatric Ovarian Tumors.

    Plevová P, Geržová H

    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2019; (32(Supplementum2)):79-91 doi:10.14735/amko2019S79.

    PMID: 31409083
  12. 12

    Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

    Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

    Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

    PMID: 39343818
  13. 13

    Person-centred care in the management of imaging-related anxiety in diagnostic radiography: A scoping review exploring cancer and non-cancer populations.

    Hughes VJ, Chapman HM, Ross T

    Radiography (London, England : 1995) 2025; (31 Suppl 2()):103218 doi:10.1016/j.radi.2025.103218.

    PMID: 41168002
  14. 14

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  15. 15

    Scanxiety Conversations on Twitter: Observational Study.

    Bui KT, Li Z, Dhillon HM, et al.

    JMIR cancer 2023; (9()):e43609 doi:10.2196/43609.

    PMID: 37074770
  16. 16

    Living with a Hereditary Cancer Syndrome: Personal Perspectives and Implications for Oncology Nurses.

    Diez de Los Rios de la Serna C, Kavanaugh S, Magalhães D, et al.

    Seminars in oncology nursing 2026; (42(2)):152151 doi:10.1016/j.soncn.2026.152151.

    PMID: 41807175
  17. 17

    Relational Aspects to Screening-Associated Distress Among Individuals With Li-Fraumeni Syndrome: "The All-Clear for Me Is Good. The All-Clear for My Kids Is Great".

    Huelsnitz CO, Werner-Lin A, Forbes Shepherd R, et al.

    Qualitative health research 2025; 10497323251365787 doi:10.1177/10497323251365787.

    PMID: 40947678
  18. 18

    Scan-Associated Distress in People Affected by Cancer: A Qualitative Systematic Review.

    Hussain M, Chau S, Turner M, Paterson C

    Seminars in oncology nursing 2023; (39(5)):151502 doi:10.1016/j.soncn.2023.151502.

    PMID: 37735038
  19. 19

    Scanxiety: a scoping review about scan-associated anxiety.

    Bui KT, Liang R, Kiely BE, et al.

    BMJ open 2021; (11(5)):e043215 doi:10.1136/bmjopen-2020-043215.

    PMID: 34039571

This page provides educational information on Ollier disease surveillance guidelines and malignancy risks. It does not replace professional medical advice. Always consult your oncology or orthopedic team regarding your specific monitoring plan.

Get notified when new evidence is published on Ollier disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.